Gene Logic Stock Up 9 Percent on Pfizer Deal; Firm Still Smarts from TherImmune Disclosure | GenomeWeb

NEW YORK, Sept. 27 (GenomeWeb News) - Shares in Gene Logic surged more than 9 percent today after the company said it will help Pfizer find new therapeutic indications for a number of its stalled drug candidates.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.